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Abstract
Metabolite profiling is being increasing employed in the study of prostate cancer as a means of 
identifying predictive, diagnostic and prognostic biomarkers. This review provides a summary and 
critique of the current literature. Thirty-three human case-control studies of prostate cancer 
exploring disease prediction, diagnosis, progression or treatment response were identified. All but 
one demonstrated the ability of metabolite profiling to distinguish cancer from benign, tumor 
aggressiveness, cases who recurred, and those who responded well to therapy. In the subset of 
studies where biomarker discriminatory ability was quantified, high AUCs were reported that 
would potentially outperform the current gold standards in diagnosis, prognosis and disease 
recurrence, including PSA testing. There were substantial similarities between the metabolites and 
the associated pathways reported as significant by independent studies, and important roles for 
abnormal cell growth, intensive cell proliferation and dysregulation of lipid metabolism were 
highlighted. The weight of the evidence therefore suggests metabolic alterations specific to 
prostate carcinogenesis and progression that may represent potential metabolic biomarkers. 
However, replication and validation of the most promising biomarkers is currently lacking and a 
number of outstanding methodological issues remain to be addressed in order to maximize the 
utility of metabolomics in the study of prostate cancer.
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Aims and Methods
The aim of this review is to summarize the existing literature where metabolomics has been 
used to evaluate prostate cancer, in order to explore potential metabolite biomarkers that 
could augment current diagnostic, prognostic or screening strategies. The metabolites and 
pathways implicated by these studies are also discussed to consider what mechanistic 
information they may impart about prostate cancer.
Pubmed was searched to identify studies of prostate cancer in humans that defined 
themselves as ‘metabolomic’ studies, or which reported metabolic fingerprints, profiles or 
signatures. Studies considering disease prediction, diagnosis, progression or treatment 
response, and studies using any biological media were considered. The references of each 
identified study were screened for further qualifying manuscripts. Studies in animal models 
and in cell lines were not included. Where the full texts were not available the authors were 
contacted.
Introduction
Prostate cancer represents the second leading cause of cancer mortality in many western 
countries and accounted for more than 28,000 deaths in the USA in 2013 (1). However, key 
questions remain on how best to diagnose and manage this cancer. In particular, the 
identification of the men at greatest risk from lethal prostate cancer, the prediction of 
treatment response and the prediction of recurrence remain challenging.
Most prostate cancers are first found during screening with a prostate-specific antigen (PSA) 
blood test, alone or in combination with a digital rectal exam, followed by a diagnostic 
biopsy and potentially imaging if there is a suspicion of cancer spread. When prostate cancer 
is diagnosed, PSA levels are utilized in tumor staging and tracking cancer progression. 
Initial treatment may be in the form of a radical prostatectomy, radiation therapy, and/or 
androgen deprivation therapy (ADT), which is based on the fact that prostate cancer growth 
is dependent on the predominant male hormone testosterone. Post treatment, PSA testing 
may again be employed to assess disease recurrence. However, there are well documented 
limitations at each of these stages. Only around 25% of men with an elevated PSA level, 
defined as> 4.0 ng/mL, are diagnosed with prostate cancer at biopsy, and conversely false-
negatives are also common (2). Biopsies frequently miss cancer due to tumor heterogeneity, 
necessitating the need for multiple repeat biopsies which are potentially hazardous to 
patients and technically challenging (3). Radical prostatectomies are associated with 
frequent co-morbidities, including erectile dysfunction and incontinence, but are associated 
with better survival outcomes that radiation therapy (4). Similarly, ADT has a number of 
adverse side effects and, on average, is only effective for two to three years before the 
emergence of castration resistant prostate cancer (CRPC); an incurable and often fatal 
disease. There are currently no known methods to predict duration of treatment response or 
to identify those men who will respond most effectively (5, 6). Furthermore, due to the 
aforementioned issues with both screening and biopsy, overtreatment represents a significant 
problem in the management of prostate cancer; the majority of diagnoses will not prove 
fatal, but there is a subset of men with aggressive and lethal disease. Identifying these men at 
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the earliest stage possible is of paramount importance to reduce to mortality from prostate 
cancer.
A number of additional biomarkers are now being explored to try and address these 
questions and challenges. This has been facilitated, to a large extent, by developments in 
high throughput sequencing technologies. Gene expression signatures have been 
demonstrated to have the ability to group patients with CRPC into high- and low-risk group 
(7) and the quantification of circulating tumor DNA in the peripheral blood has been shown 
to determine prognosis and monitor treatment effects (8). However, the development of 
novel prostate cancer biomarkers is still in its infancy. Increasingly, metabolomics is being 
explored to address this need. This high-throughput methodology has the dual benefit of 
identifying biomarkers while also enabling a better understanding of the underlying disease 
mechanisms.
Metabolomics has been applied as an interdisciplinary “omics” science combining pattern 
recognition approaches and bioinformatics with epidemiology, analytical biochemistry and 
biology in the study of the ‘metabolome’(9), which has been defined as ‘the quantitative 
complement of all of the low molecular weight molecules present in cells in a particular 
physiological or developmental state’ (10). Metabolomics provides a down-stream measure 
of a whole system's activity that reflects the genome, epigenome, transcriptome and 
proteome, and their interactions with the environment (11). The metabolome, as a measure 
of systemic activity, has also been shown to be indicative of the disease state (12). In 
particular neoplastic cells are known to possess unique metabolic signatures (13), including 
aerobic glycolysis (also known as the Warburg effect characterized by increased glucose 
uptake and lactate production) and production of choline containing compounds (9, 14-16). 
Accordingly, a number of studies have attempted to capture metabolomic biomarkers of 
prostate cancer.
Prostate cancer represents a particularly attractive model for metabolite profiling. First, there 
is strong evidence to suggest that dysregulation of metabolism plays an important role in the 
development and progression of this malignancy. One of the most consistently cited risk 
factors is metabolic syndrome; a collection of patho-physiological entities including visceral 
obesity, insulin resistance, low HDL-cholesterol, high triglycerides, elevated C-reactive 
protein, and low adiponectin levels (17). This syndrome is associated with chronic 
inflammation and high concentrations of inflammation-related markers, which are thought to 
enhance tumor growth (18). Second, the healthy prostate is known to exhibit a unique 
metabolism to produce the components of prostatic fluid: PSA, spermine, myso-inositol and 
citrate. In fact the levels of citrate in the prostate are orders of magnitude higher than 
anywhere else in the body (19, 20). In addition to the metabolic features common to all 
malignancies, neoplastic prostate cells also lose the capacity to accumulate zinc which is 
thought to inhibit the ability to accumulate citrate. The metabolomic alterations reflecting 
this phenomenon, which is unique to prostate cancer cells, are hypothesized to result in a 
distinctive and specific metabolome that can be captured through metabolomic profiling.
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Selected studies
A search of the peer-reviewed literature identified a total of 33 qualifying studies (table 1). 
The term ‘metabolomics’ was not coined until 2002 by Fiehn et al. (21). However 
researchers have been exploring the measurements of multiple metabolites as potentially 
useful biomarkers of prostate cancer for many years. Therefore, three studies predating this 
specific terminology which attempted to characterize a ‘metabolomic profile’ are also 
included. Since 2002 there has been a steady increase in the number of metabolomics 
studies, with more than half of the selected studies published from 2011 onwards.
Study Designs and Methods
The included studies fell into five broad groups based on their stated aims; studies 
attempting to identify predictive biomarkers prior to diagnosis (n=2) (22, 23), studies aiming 
to distinguish malignant from benign (n=19) (24-42), studies considering biomarkers of 
tumor aggressiveness (n=1) (43), studies investigating the effect of therapy (n=3) (44-46), 
and studies considering multiple outcomes (n=8) (16, 47-53). In common with the majority 
of the existing metabolomics literature (54), all studies were case-control in design; 
including two nested within cohorts (22, 23). Twenty-two studies used external controls who 
were either healthy (n=13 studies) (22, 23, 34, 37-42, 49-52), suffering from benign prostatic 
hyperplasia (BPH) (n=3) (26, 29, 53), non-recurrent cases (n=2) (45, 48) or they included 
multiple control groups (n=4) (25, 35, 36, 43). In the remainder, the prostate cancer cases 
acted as their own controls through the use of matched biological samples or the 
measurement of metabolites pre-and post-therapy. The most commonly utilized biological 
sample was prostate tissue (n=14), followed by blood (n=10), urine (n=5) and expressed 
prostatic secretions (n=1 study). Additionally, three studies used a variety of media (table 1).
The two most commonly used methods for performing metabolomics studies are mass-
spectrometry (MS) and Nuclear magnetic resonance spectroscopy (1H-NMR). MS involves 
ionization of chromatographically separated chemical compounds and detection based on 
their mass-to-charge ratio and retention time during chromatography. Consequently 
detection of metabolites by MS is biased towards those that ionize most efficiently. 
Nevertheless, MS it is the more sensitive of the two techniques and can be performed with 
smaller amounts of a biological sample; an important consideration in large scale human 
studies. The second method, NMR, subjects a sample to an electromagnetic field and 
measures the characteristic radio waves displayed by each compound in the sample in 
response to changes in the magnetic field. For a mixture of metabolites in a biological 
sample the different patterns of energy release are represented as peaks in a chromatogram, 
and the area of the peaks is proportional to the concentration of each metabolite (19). NMR 
is a more analytically reproducible method. does not require sample separation, and provides 
both quantitative and structural information (55). However, because sensitivity is limited it is 
only able to detect a smaller range of metabolites (2, 19). The majority (n=21) of the 
selected studies performed metabolomic profiling using Mass spectrometry (MS), with the 
remainder employing Nuclear Magnetic Resonance (NMR) based techniques.
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Metabolite identification
Metabolomic studies generally fall into two classes; (1) targeted studies which focus on the, 
often quantitative, measure of specific metabolites, sometimes selected on the basis of 
biological rationale, and (2) untargeted studies with no a priori hypothesis which measure a 
much larger number of metabolites, but the exact identity of many metabolites detected by 
untargeted MS is not apparent without further study. Seventeen studies took an untargeted 
approach to the search for discriminatory metabolites, with only 12 employing a targeted 
search. The targeted approach introduces an inherent bias as it is only able to detect the 
specific metabolites or metabolite classes, such as methionine metabolites (48), corticoids 
(35), or lipids (29, 40), which have been previously determined. However, it should be noted 
that the quantitative nature of the targeted studies offers the distinct advantage of easier 
translation into a clinical setting. Even with a ‘hypothesis-free’ approach there is not a single 
analytical methodology that can, even closely, cover the whole metabolome, which is 
estimated to lie within the range of 104 to 105 metabolites (54). Thus, untargeted approaches 
also carry with them some bias based on their chosen methods such as the chromatography 
and detection techniques used to measure metabolites.
The number of metabolites identified in the selected studies varied by orders of magnitude 
and was dependent on the methods and technologies employed. Some studies reported the 
number of peaks, spectral regions or metabolite features, which may not necessarily 
correspond to individual metabolites. Furthermore, while some studies included all 
metabolites in their analyses, others restricted analysis to those metabolites which could be 
annotated. This may complicate the interpretation and translation of the findings. In those 
studies including all metabolites, the unknowns cannot be biologically interpreted and 
potentially important information linking the metabolites with the disease process may be 
missed, furthermore any pathway analysis will be inherently biased towards the known 
metabolites. Conversely, studies restricting to known metabolites may miss important 
components in metabolomic signatures reducing their discriminatory ability. When 
comparing between the two types of study studies it is difficult to know whether replication 
was not achieved because it did not exist, or because of differences in the metabolites 
compared. To date, the definitive annotation of identified metabolites remains a bottleneck in 
untargeted metabolomics studies; absolute identification and quantification can only be 
made in the presence of an authentic standard. Only seven of the included studies were 
quantitative or semi quantitative in nature (16, 32, 35, 39, 47, 48, 50).
Statistical analyses
Regardless of the technological methods used, complex analytical methods are required to 
deal with the multivariate, highly collinear noisy datasets produced (56, 57). Metabolomics 
studies often employ pattern recognition or clustering techniques as a means of reducing 
dimensionality including unsupervised methods, such as principal components analysis 
(PCA) which converts a set of observations into a set of linearly uncorrelated variables 
called principal components, and supervised methodologies, such as orthogonal partial least 
squares – discriminant analysis (OPLS-DA) a related method that is able to separate the 
components into predictive and uncorrelated information (9). These were employed by 15 of 
the selected studies, with the others using more classical statistical methods, including t-tests 
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and regression modeling. One study used a novel feature selection algorithm termed 
associative voting (49), which integrates class association rule data mining and 
classification, and one utilized an entirely pathway based approach: subpathway-GM (33) 
which maps genes and metabolites of interest to metabolic pathways in order to identify 
biologically relevant subpathway regions (readers are referred to (49) and (33) for full 
methodological details). In fact, the subpathway-GM method revealed novel associations 
beyond the original analyses of the same dataset using a more classical statistical approach 
(52). Thus pathway-based methods for analyzing metabolomics data may help to provide an 
improved mechanistic interpretation, but are limited by the fact that they are entirely reliant 
on the underlying databases utilized (58), and currently comprise only a small percentage of 
the metabolomics literature.
Results
The selected studies indicated that distinct clusters based on metabolite profiles could be 
identified in a variety of biological media including blood (40, 41, 51), urine (36, 38, 42), 
tissue (16, 28, 31, 32, 45, 47, 52) and expressed prostatic secretions (39). These clusters 
were able to distinguish cancer from benign (28, 31, 32, 36, 38-42, 47), tumors by their 
degree of aggressiveness (16, 32, 47), cases who recurred (45), and those who responded 
well to therapy (51). The distinction between the groups of interest on the basis of their 
metabolic profiles suggested that the development of metabolomics-based biomarkers may 
be possible. Although all included studies were ultimately interested in the identification of 
discriminatory metabolites or profiles, seventeen of the studies specifically aimed at the 
development and assessments of biomarkers either for diagnostic or prognostic purposes, 
and evaluated the utility of these biomarkers using receiver operator characteristic (ROC) 
curve analyses and indices of specificity and sensitivity. In the first part of the results 
section, the findings of these 17 studies (table 2) will be explored. In the second part these 
findings will be placed in a wider biological context using the results of the remaining 16 
papers (table 3), which did not explicitly search for, or assess biomarkers. The final part will 
detail the attempts at replicating and validating these findings.
Part 1: Assessing biomarkers
Biomarkers of Prostate Cancer—Nine of the studies comparing malignant and non-
malignant prostate cancer samples reported AUCs for diagnostic accuracy ranging from 0.67 
for urinary sarcosine levels in a USA based case-control study (52) to 0.982 for a biomarker 
profile including phosphocholine and choline, that was developed by comparing tumor to 
benign prostate tissue from the same patients (28). The second highest reported AUC was 
0.973 from Zhou et al.'s case-control study. This blood-based profile included 15 
phosophocholine containing species, and although an AUC was not computed, Giskeødegård 
et al. also included phosphocholine in their tissue-based biomarker profile, which had a 
sensitivity and specificity >85% (47). Three of the papers (34, 39, 52) reported the AUC for 
individual metabolites, with acylcarnitine ranking the highest (AUC: 0.97 in plasma) (34). 
Carnitines were also identified in Struck-Lewicka et al.'s diagnostic signature in urine. 
Similarly citrate, which had an AUC of 0.89 in Serekova's study (39) and was a component 
of Giskeødegård et al.'s signature (47). The remaining studies reported on profiles 
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comprising multiple markers. Interestingly there was some crossover between the profiles 
developed in the case-control studies of Osl et al.(49), Miyagi et al.(50), Zang et al.(41) and 
Struck-Lewick et al. (42), with all including multiple amino acids such as lysine, glutamine 
and ornithine in their profiles. Osl et al. also included arachidonic acid in their signature, a 
compound related to arachidonoyl amine, which was reported to have an AUC of 0.86 in 
Lokhov et al.'s study (34). Further, Osl et al. included a number of phosphorylcholines, in 
agreement with the findings of Zhou et al.'s targeted lipidomics analysis, while Zang et al. 
identified multiple lysophospholipids. The sensitivity and specificity of Zang's diagnostic 
profile, which also contained metabolites of the steroid hormone biosynthesis pathway and 
bile acids, was 92%, and 94% respectively. Struck-Lewicka et al. also did not report AUC's 
but rather, the R2 and Q2 values for their partial least squares-discriminant analysis model 
which were 0.789, 0.711 respectively, under the best performing GCMS derived model, 
indicating a robust signature with good predictive ability.
The studies by Osl, Miyagi, Zhou, Zang and Lokhov et al. developed their signatures in 
blood samples, and it is of note that there was little crossover in terms of the specific 
constituent metabolites with the urine-based diagnostic signatures proposed by Zhang et al. 
(38), Struck-Lewick et al. (42) or Wu et al.(36). All but two of the studies (28, 47), 
compared prostate cancer cases to healthy controls. However, the results of Giskeødegård 
and Cheng's inter-individual comparisons among prostate cases were markedly concordant 
with these healthy versus diseased comparisons, both in terms of the constituents of the 
signatures they developed including phosphocholines, and citrate, and in the predictive 
ability of these signatures. Similarly, study population size which ranged from 40 (20 
prostate cancer cases and 20 healthy controls) in Wu et al.'s study (36) to 800 (134 cases and 
666 controls) in Miyagi et al.'s study, did not appear to confer any advantages in terms of the 
predictive ability of the developed signature.
In summary, the most promising candidate biomarkers for distinguishing prostate cancer 
cases from healthy controls include sarcosine, choline, phosphocholines, 
phosphorylcholines, carnitines, citrate, amino acids, arachidonoyl amine and 
lysophospholipids (table 2).
Biomarkers of Benign Prostatic Hyperplasia (BPH) and tumor aggressiveness
—Wu et al. also reported on a biomarker profile with an AUC of 0.825 to distinguish BPH 
and prostate cancer patients constituting five metabolites. All five; dihyroxybutanoic acid, 
xylonic acid, pyrimdine, xylopyranose, and ribofuranoside, were also constituents of the 
healthy versus diseased profile. Hahn et al. reported that MRS spectra could be used to 
classify benign and malignant prostate tissue with a sensitivity of 100%, a specificity of 96% 
and an overall classification accuracy of 97%, with citrate, glutamate and taurine playing 
important discriminatory roles (26). Fan et al.'s 9-feature profile had an AUC of 0.876 for 
distinguishing prostate cancer and BPH patients. Similar to their malignant versus benign 
analyses this serum-based signature included glutamate, lysine and lipid species, suggesting 
a possible dose dependent relationship with the progression from normal to BPH to cancer. 
However Fan et al. found that the signature did not perform well at distinguishing Gleason 5 
from Gleason 7 (AUC: 0.532) or organ-confined from non-organ confined cancers (AUC: 
0.311).
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Three other papers also developed biomarker profiles of tumor aggressiveness. Osl et al. 
compared Gleason 6 with Gleason 8-10 cancers, and reported that the discriminatory 
metabolites, which included a number of Sphingomyelin lipids, were distinct from those that 
differed between normal and tumor tissue. However the AUCs were much lower in the 
tumor aggressiveness analyses suggesting discriminatory power is poor. Conversely, Miyagi 
et al. reported increasing AUCs when comparing healthy controls to Stage II patients (AUC 
0.764), Stage III patients (AUC: 0.777) and Stage IV patients (AUC: 0.873) using a profile 
comprising 8 amino acids; Alanine, Isoleucine, Ornithine, Lysine, Glutamine, Valine, 
Tryptophan and Arginine. McDunn et al.'s study the AUC for a combination of four different 
biomarkers; 5,6-dihydrouracil, glycerol, methylpalmitate and choline phosphate, was 0.62 
for discriminating organ-confined from non-organ confined prostate cancer.
In summary, the most promising candidate biomarkers for identifying BPH and tumor 
aggressiveness include dihyroxybutanoic acid, xylonic acid, pyrimdine, xylopyranose, 
ribofuranoside citrate, glutamate, Sphingomyelin lipids, amino acids, 5,6-dihydrouracil, 
glycerol, methylpalmitate and choline phosphate (table 2). Again, there was little difference 
in the results between those studies that compared healthy individuals to prostate cancer 
cases and those investigating inter-tumor differences within controls, or any differences due 
to study population size.
Biomarkers of disease recurrence—Interestingly, Choline phosphate 
(phosphorylcholine) was also identified as a major contributor to the metabolic profile 
predicting recurrence by Maxeiner et al. (45), which had an AUC of 0.78. This profile was 
based on the first nine principal components of all the measured metabolites and the 
loadings plots determined that myo-inositol and spermine, both of which were identified in 
Serkova et al.'s diagnostic signature, and glutamate, which was a component of Fan et al.'s 
aggressiveness signature, were major contributors to the recurrence profile.
Similarly cysteine, a further component of Fan et al.'s aggressiveness signature, was 
investigated as a marker of recurrence by Stabler et al.(48). This metabolite was found to 
have an AUC of 0.82 when combined with PSA, outperforming two other methionine 
metabolites: homocysteine (AUC: 0.78) and cystathionine (AUC: 0.79). When these three 
metabolites were combined the AUC was 0.86, providing an increased ability to detect 
recurrence over clinical indices alone.
Although Menard et al. (44) did not perform ROC analysis their profile, including choline, 
creatine, glutamine and lipids, was able to identify a malignant biopsy following 
radiotherapy with a sensitivity 89% of, a specificity of 92%, and an overall classification 
accuracy of 91%.
Despite the differences in study designs; Menard et al. and McDunn at al. considered inter-
tumor differences, while Maxiener et al.(45) and Stabler et al. (48) compared the recurrent 
and non-recurrent cases in tissue and in blood and urine respectively, the results were largely 
concordant between the studies. It is also of note that the smallest predictive ability was 
reported for the largest study (16). In summary, the most promising candidate biomarkers for 
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predicting disease recurrence included phosphorylcholine, myo-inositol, spermine, 
glutamate, cysteine, choline, creatine, glutamine and lipids (table 2).
PSA testing and current gold-standards—Prostate cancer is a relative rarity amongst 
malignancies in that it has been shown to be amenable to population wide screening 
programs utilizing PSA, which is also monitored as a biomarker of biochemical recurrence 
(6) Therefore novel biomarkers must perform better than this current gold standard in order 
to be useful. Seven of the studies discussed above explicitly compared their biomarkers to 
the use of PSA (34, 39-41, 48, 52, 53). An often cited study reports an AUC for PSA testing 
of 0.682 (95% confidence interval [CI] 0.67–0.69) for the diagnosis of prostate cancer, and 
that a PSA cutoff value of 4.1ng/ml has a specificity of 93.8% but a sensitivity of only 
20.5% (59). Zhou et al.'s multi-marker plasma metabolite profiles outperformed these 
metrics in diagnosis (40), although parsimony must also be taken into account when 
considering clinical translation. Similarly, Serkova et al. reported AUCs for three 
metabolites that would outperform PSA, and added that, unlike PSA, they are not associated 
with age, suggesting improved specificity. Although it should be noted that Serkova was 
comparing the discriminatory ability of these metabolites in expressed prostatic secretions to 
a blood-based PSA test. Lokhov, Zang and Stabler et al. computed the utility of PSA in their 
respective study populations for the diagnosis of prostate cancer (Lokhov and Zang et al.) 
and the prediction of recurrence (Stabler et al.), and all reported that their blood-based 
biomarkers outperformed PSA. Although the serum biomarker profile developed by Fan et 
al. outperformed PSA at distinguishing BPH from prostate cancer in their population, it was 
comparable or inferior to PSA testing in discriminating tumors by their degree of 
aggressiveness. Finally, Sreekumar et al. reported that the measurement of sarcosine in urine 
was superior to PSA at predicting a positive prostate cancer biopsy within the clinical PSA 
grey zone of 2–10 ng/ml.
For the tissue based diagnostic studies (26, 28, 47), the current gold diagnostic standard is 
histopathology, but as histopathologic analysis is used to determine the presence of prostate 
cancer it cannot be compared to metabolomics profiling. Nevertheless in all the studies, 
good correlation between the metabolic findings and the histopathological findings was 
demonstrated. Furthermore for disease recurrence, McDunn et al. reported that the inclusion 
of a metabolomics profile afforded increased prediction compared to clinical indices alone.
Part 2: Hypothesis generating studies
Metabolites and pathways implicated in prostate cancer tumorigenesis, 
progression and recurrence—In the remaining metabolomics studies, the primary aim 
was not the identification of biomarkers or indices of biomarker utility were not reported 
upon. However, among the results there was substantial crossover with the metabolites and 
pathways discussed in part 1, in particular with those thought to be involved in pathogenesis. 
In studies comparing prostate cancer patients to healthy controls, differences in metabolites 
and pathways relating to energy metabolism were reported including TCA cycle 
intermediates (24, 27, 32), lactate (24, 32), citrate (23), phosphoenolypyruvate, and 
adenosine diphosphate (32) Metabolites vital to cell growth and proliferation were also 
identified; these included common amino acids (15, 30) bile acids (60), polyamines (27), 
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glycerol-3-phosphate (30) and a number of constituents of cells membranes including long 
chain fatty acids (22, 23, 51), phospholipids (30), phosphocholines (61) and choline (27) 
(55). Steroid hormones (23) which help regulate the growth and function of the prostate 
were also implicated (62), as were inositol and its isomers (27) which are involved in 
osmoregulation, and have been shown to be dysregulated in several other cancers(55) and 
cortisol (35) which is thought to be related to cancer development via the mechanism of 
chronic stress (63).A number of these metabolites; citrate, inositol, lactate (25) and cortisol 
(35, 63), were additionally observed to differ between BHP and prostate cancer patients, 
along with phosphoethanolamine, and glycerophosphoethanolamine (29) which are also 
components of membranes and acetate (25) which is thought to support cell proliferation 
through de novo lipid biosynthesis (64).
Levels of metabolites including sarcosine, uracil, kynurenine, leucine, and proline (43) were 
shown to be increased during the progression to metastatic disease (32, 33, 43), as were 
pathways involved in nitrogen breakdown (43). Nitrogen metabolism is known to be altered 
in tumors to accommodate their enhanced glutamine requirements and the increase in 
nucleotide and protein synthesis (65). Arachidonic acid metabolism was also altered which 
is in line with the suspected association between dietary fat and prostate cancer (33, 66). 
Metabolites from the pathways of energy and lipid metabolism were again demonstrated to 
be of importance (23, 43) in the degree of disease aggressiveness. Taken together with the 
results of the biomarkers studies, these findings suggest a particularly important role for 
pathways involved in abnormal cell growth and intensive cell proliferation in prostate 
carcinogenesis and progression. Dysregulation of lipid and fatty acid metabolism may be 
particularly crucial to the disease process.
Multiple steroids, markers of lipid beta-oxidation, markers of omega-oxidation and markers 
of insulin resistance (67) were observed to decrease following therapy in the study by Saylor 
et al. (46), while bile acids (60) steroids, and their metabolites increased. This was in line 
with the findings of Huang et al. (51), who reported that the metabolite profiles of patients 
successfully treated with endocrine therapy, closely resembled those of healthy controls. 
Among all the included studies one did not report any significant findings (37). This study, 
by Gamagedara et al. was targeted to only four metabolites that had previously been reported 
as significant in tissue. As it discussed further in the following section it is perhaps not 
surprising that they were unable to replicate the findings in a different biological media. 
Further they were unable to reliably measure the strongest candidate, sarcosine. 
Nevertheless, it must be taken into consideration that the very small number of null findings 
may reflect more on the bias towards publishing studies with positive findings, than on the 
application of metabolomics profiling.
Part 3: Replication and Validation
In order to validate their findings eleven studies used internal cross-validation methods (16, 
26
, 
40
-
44
, 
47
, 
49
, 
50
, 
53), while one compared the tissue metabolomics findings to those 
obtained by histopathology (27). Two further studies reported that validation in independent 
cohorts was ongoing at the time of publication (39, 51) but this data is not yet publically 
available. Two studies (22, 23) were based within the same parent cohort, but there was no 
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overlap between the populations included. The same metabolite classes were identified as 
potentially predictive biomarkers in the both studies, and a meta-analyses of the findings 
provided robust results, particularly for aggressive disease.
Only two studies attempted replication of their findings in an entirely independent cohort 
(38, 52). Zhang et al. compared an additional 30 prostate cancer patients from a different 
geographic region to their original control population, reporting that 14 of 33 (42%) putative 
diagnostic biomarkers retained statistical significance. These included four novel 
metabolites; ureido isobutyric acid, indolylacryloyglycine, acetylanilalinine and 2-
oxoglutarate. After isolating sarcosine as a differential metabolite between benign and 
prostate cancer tissue samples, Sreekumar replicated the experiment in 89 independent 
samples and reported that not only were sarcosine levels in tissue significantly increased in 
the cancer specimens there was a further increase among patients with metastatic disease, 
thereby both confirming and extending upon their original findings.
Sreekumar et al. further explored the potential of urinary sarcosine, observing significantly 
increased levels in biopsy positive patients. Two other studies (43, 48) also used multiple 
biological media. Stabler et al. only replicated one of their markers of recurrence, cysteine, 
between urine and serum blood samples. Thysell et al. looked at bone, tissue and plasma, 
again they only replicated a small number of metabolites between media, and none were 
common to all three. Finally, Brown (31) and Shuster et al. (30) analyzed the same eight 
prostate samples using different statistical techniques. They reported similar results and both 
concluded that a metabolic approach could reliably distinguish benign and cancerous 
samples and indicate tumor aggressiveness. In the remaining studies no attempt at 
replication was made.
The Sarcosine Debate—Following the publication of Sreekumar et al.'s findings on 
sarcosine, an intermediate and byproduct in glycine synthesis and degradation, a number of 
studies attempted to replicate these promising results. Li et al.'s (33) pathway-based analysis 
of Sreekumar et al.'s dataset reported an association between metastatic prostate cancer and 
methionine metabolism pathways, which can be involved in the formation of sarcosine. 
McDunn et al. (16) observed significantly elevated sarcosine levels in Gleason grade 8 
tumors or higher compared to benign tissue, while Thysell et al. (43) found a significant 
increase in sarcosine in the bone of men with metastatic disease. Although recurrence was 
not a focus of Sreekumar et al.'s original study, Stabler et al. (48) observed that urinary 
Sarcosine levels at the time of surgery were significantly higher among those men whose 
cancer subsequently recurred.
Conversely, Wu (36) and Zhang et al. (38), reported no significant differences in urinary 
sarcosine levels between prostate cancer cases, BPH cases and healthy controls, and 
sarcosine was not significant in Mondual et al. (2014)'s blood-based study (22). Contrary to 
their findings in bone, Thysell et al. found no association between prostate cancer and 
sarcosine levels in blood or tissue (43). Sarcosine could not be reliably measured in two 
further studies (30, 37), however Shuster et al. replicated Sreekumar et al.'s positive findings 
for uracil, kynurenine, glycerol-3-phosphate, leucine and proline levels in tissue (30), while 
Gamagadara et al. observed no diagnostic potential for these metabolites in urine.
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It has been suggested that these differences in findings may be the result of technical 
differences between the studies. It is it notable that is it analytically challenging to precisely 
and accurately measure sarcosine, particularly at low concentrations (68), as is evidenced by 
the two studies that were unable to do so (30, 37). It has been suggested that liquid 
chromatography for sample separation prior to MS, may be preferable to gas 
chromatography for the measurement of sarcosine and that this may explain the conflicting 
findings (68). However, within the studies reported here; a combination of liquid and gas 
based chromatography was used by both the studies reporting positive findings (16, 43, 48, 
52) and those reporting null findings (22, 36, 43, 69). The studies were also coherent with 
regards to the statistical analyses performed; comparisons of means, OPLS-DA and ROC 
curves. With the exception of McDunn et al., all compared to prostate cancer cases to 
controls and there was no striking differences in population sizes between the positive and 
null studies. It has also been suggested that population differences in sarcosine levels may 
lead to false-negative or false-positive findings. Among the studies reporting positive 
findings, three were based in the USA (16, 48, 52) and one in Sweden (43), while among the 
null studies, two were based in Asia (36, 38) and two in Europe (22, 43). However, the 
explanation for the differences in findings most likely relates to the multitude of technical 
challenges and that in particular in the urine-based studies the difficulty in accurately 
determining the sarcosine/creatine ratio is likely to be playing a role (36, 68).
Methodological Considerations
Comparisons with other cancers
One of the most common applications of metabolomics is in the study of cancer (54), and a 
number of metabolomics biomarkers with discriminatory abilities comparable to or even 
better than those for prostate cancer have been proposed, particularly in cancers of the 
gastrointestinal system (70-72) and pancreas (73, 74). Malignant cell are known to possess 
metabolic phenotypes that differ from many normal tissues, characterized by a shift toward 
aerobic glycolysis and pathway alterations that support biomass accumulation for cell 
proliferation (14, 15, 75, 76). As such these reported findings, particularly in the non-tissue 
based studies, may identify signatures that reflect malignancy in general and which are not 
specific to prostate cancer. With this possibility in mind, seven studies investigated 
additional malignancies (24, 31-33, 37, 43, 50).
Halliday et al. (24) compared the metabolic profiles of prostate cancer, lung cancer and 
colon adenocarcinoma, and reported tumor specific differences. Similarly, Kami et al. (32) 
detected a clear distinction between lung and prostate cancer samples based on their 
metabolic profiles, and reported that lung versus prostate differences were greater than 
normal versus tumor differences within the same organ. However they did note that 
compared to their normal counterparts both tumor types shared a number of features such as 
higher levels of amino acids, lactate, succinate, fumarate, and malate. Intriguingly, these 
TCA intermediates have also been shown to be increased in both colon and stomach cancer 
(77).
Conversely, Gamagedara et al. who investigated the biomarkers identified by Sreekumar et 
al. in urine reported that in their population these biomarkers could not distinguish between 
Kelly et al. Page 12
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
prostate cancer cases and controls, nor could they distinguish prostate from breast cancer. 
While Thysell et al., who considered breast, esophageal, lung and kidney cancer, observed 
that the significant differences in sarcosine levels between normal bone and the bone 
metastases of prostate cancer patients were also evident in these other cancers, indicating 
such differences may not be prostate cancer specific.
Three other studies investigated additional cancers, including kidney (31), colorectal 
adenoma (33), lung, colorectal, breast and gastric cancer (50), although they did not 
specifically compare the metabolome of these malignancies to prostate cancer. A common 
theme between all cancers was a significant alteration in amino acid levels. A large number 
of differential metabolites were identified for all the investigated cancers, including prostate, 
particularly among the amino acids. Nevertheless, Miyagi et al. reported that the greatest 
proportion of differential metabolites were tumor site-specific.
In summary, in these studies a prostate cancer specific metabolome was demonstrated both 
in tissue (24), and in plasma (50), although these metabolomes are characterized more on the 
basis of the patterns and behaviors of groups metabolites including lipids and TCA cycle 
intermediates, rather than on individual metabolites. A prostate cancer specific metabolome 
was not demonstrated in urine (37).Within the wider cancer metabolomic literature; a 
number of the putative ‘prostate biomarkers’ discussed in this review have also been 
proposed as biomarkers of other malignancies. Aspartic acid, 2-hydroxybutyrate and 
kynurenine, have been suggested as metabolomics biomarkers of colorectal cancer; the 
malignancy in which the field of metabolomics is perhaps most advanced (78). Lactate, 
threonine, acetate, uracil, succinate, lysine and tyrosine, myo-inositol, taurine and creatine 
have been shown to be associated with the presence of rectal cancer, and correlated with its 
progression (79). Taurine is also increased in squamous-cell carcinoma (80), while lactate 
has additionally been shown to be associated with oesophago-gastric cancer (81), along with 
fumurate, valine, glutamine, glutamate (81), xylonic acid (81, 82), tyrosine, phenylalanine, 
and tryptophan (83). Together these metabolites indicate a general dysregulation in the 
metabolism of cellular respiration, energy, amino acids, ketone body and choline metabolism 
which, as discussed, could be applicable to all cancers. Similarly, choline, phosphocholine, 
phosphatidylcholine, lysophosphocholine and glycerophosphocholine, which are necessary 
for cell membrane synthesis and intercellular signaling (55),have been identified in 
metabolomic profiling studies of multiple cancers including brain, breast, lung and liver 
(84). One of the prostate diagnostic biomarkers with the highest reported AUCs, 
acylcarnitine in blood, has also been shown to distinguish kidney cancer patients from 
controls, and by their degree of severity when measured in urine (85); this is hypothesized to 
reflect alterations in immune surveillance and again may point to the overall phenotype 
required to support the growth and proliferation of malignant cells. Even citrate, which 
could have been hypothesized to be prostate cancer specific given its importance in the 
prostate has been shown to be increased in bile samples of patients with biliary tract cancers 
(86).
In fact, the vast majority of the metabolites reported here have also been identified in other 
studies supporting the concept of a carcinogenesis metabolome. However, tumors still retain 
much of their unique organ specific metabolism (32, 75), and to date neither spermine nor 
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sarcosine have been proposed as metabolomic biomarkers of any other malignancies. 
However whether this denotes these metabolites as prostate specific, or it merely reflects the 
nature of metabolomics and the possibility these metabolites have not been measured in the 
profiling of other cancers, remains to be seen.
Technological and analytical issues
In addition to the ‘epidemiological validation’ of findings through replication, is it also vital 
to show that a proposed biomarker displays ‘technical validation’ in terms of intrinsic 
measurement error and analytic sensitivity (87). Much of the between-study heterogeneity 
and inconsistency can be attributed to the use of differing technological, experimental and 
analytical methods, which can affect the measurements of metabolites in an as yet to be 
determined way (88). Only seven studies reported on their quality control (QC) procedures, 
to allow the consideration of system stability, with varying degrees of detail (22, 23, 35, 38, 
42
, 
46
, 
51). While only eight (22, 23, 30, 35, 38, 42, 46, 51), reported on the relative 
standard deviation (RSD%) threshold for the included features (38).
Bias and confounding
In order to fully understand the impact of disease, the composition of the ‘normal’ 
metabolome in healthy individuals must also be established. The metabolome will be 
dependent on the originating tissue or biological media, but will additionally vary by age, 
BMI, diet and other lifestyle factors (89). This is further complicated by the fact that a 
genetic component to the metabolome has been demonstrated (90). There is also a wide 
range of stability among metabolites and those metabolites that are more stable, including 
amino acids, are more likely to show differences if they exist between cases and controls. 
The temporal fluctuation of the metabolome also introduces novel challenges particularly in 
those studies assessing recurrence and treatment response, and it is of note that none of the 
diagnostic or aggressiveness studies utilized repeat measurements to address this (87). 
Similarly none of the studies addressed the temporal fluctuation in the metabolome through 
the use of repeat samples.
Consequently as well as technologically induced variation, confounding represents an 
important issue in any metabolomics study (91). In epidemiological studies of prostate 
cancer a number of potential confounders are commonly included in statistical models 
including age, race, BMI and often Gleason grade, due to their reported associations with 
prostate cancer independence, progression and lethality (92, 93). Importantly these variables 
may also affect the metabolome (94, 95). However they were rarely taken into account in the 
selected studies.
The impact of inter-individual variation represents a strong argument for cases acting as 
their own controls (96), and in ten of the studies intra-tumor differences within the same 
patients were compared (16, 24, 27, 28, 30-33, 44, 47). Similarly, Saylor et al. compared 
blood samples pre- and post- therapy (46). The remainder utilized external controls. 
Although the use of external controls ensures that the comparison group is ‘healthy’ and not 
subject to underlying or latent disease pathology, it also introduces the potential for false 
positives to arise through batch effects or confounding. Among the studies in this review the 
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majority of blood and urine based studies utilized external controls, so it is difficult to assess 
whether this resulted in an excess of positive findings. Eight studies matched on age (22, 23, 
41
, 
42
, 
45
, 
50
, 
51
, 
97), four on sampling time (22, 23, 43, 45), one on Gleason grade (45) 
and one on BMI (42). However, neither age (39, 40), smoking status (22, 50), clinical 
variables (48), BMI, serum cholesterol, educational level nor various dietary factors (22, 23) 
were found to act as confounders in those studies where they were considered. Confounding 
was not addressed in the remainder of the studies, and none considered other potentially 
important factors such as subtype heterogeneity (98). Treatment was shown to be a further 
modifier of the metabolome in the studies investigating its effect (46, 51), and although six 
studies stated that the biological samples were collected prior to any radiation or hormonal 
therapy (32, 36, 47-50), one study included metabolic profiles ascertained post therapy (43), 
and the remaining case-control studies did not report on this covariate.
The majority of the studies were conducted in predominantly Caucasian populations with 
the exception of six Asia-based studies (32, 35, 36, 38, 50, 51), and only two studies (40, 41) 
reported on the ratio of races within their study. This is of particular importance given the 
largely unexplained disparities in prostate cancer incidence between ethnicities (99), 
however in Zhou et al.'s (40) study race was not found to act as a confounder. Of the 
remaining studies, 19 were based in North America and eight were based in Europe, 
therefore given the suspected impact of environmental and dietary factors on the 
metabolome, the wider generalizability of the reported findings must be considered.
Multiple testing
Despite the high-dimensional nature of metabolomics, only five of the selected studies 
controlled for multiple testing (16, 22, 23, 47, 52). Although the significant findings reported 
in these three studies were robust to such correction, many applied a nominal significance 
level of 0.05 regardless of the number of metabolites under investigation. There was 
additional possibility of false positives arising in those studies comparing multiple biological 
media. Only four studies (16, 40, 50, 53) reported on the statistical power of their approach 
in the search for discriminatory metabolites.
Biological samples
The media in which a biomarker can be reliably measured is of importance in the 
consideration of its forward translation. The tissue-based biomarkers would have no utility 
in predicting incident disease, and even for diagnostic or prognostic purposes blood and 
urine can be obtained in a less invasive and more cost-effective fashion. Furthermore, tissue 
is a limited resource, and it may be prudent to preserve it for other uses including subsequent 
histopathological analysis. Disease associated metabolites tend to be more concentrated the 
closer in proximity they are to the organ of interest (30), however only one study considered 
prostatic secretions (39), possibly due to challenges related to its collection. Interestingly the 
use of tissue did not appear to confer any advantages over the other biological specimens, 
with some of the strongest results reported in blood samples.
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Discussion
Because widely used PSA testing remains somewhat controversial (36, 100, 101), additional 
biomarkers that could help refine practices would be a welcome addition to the management 
of prostate cancer. With the advancement of high-throughput technologies, metabolomics is 
emerging as a promising tool in biomarker development (9, 12, 69, 91, 102-106). Its 
downstream nature provides a holistic picture of the malignant state and consequently 
insight into dysregulated metabolic pathways and inherent disease development. The 
selected literature provides encouraging results in the field of prostate cancer, however it 
also demonstrates the novel challenges faced by metabolomics, which are only just 
beginning to be addressed.
The metabolomics of prostate cancer remains a small field with the majority of studies 
focused on the identification of biomarkers to distinguish malignant and benign prostate 
tissue, with few studies investigating disease progression and treatment response. Only two 
studies to date have employed a prospective design to look for predictive biomarkers (22, 
23). Therefore important issues of cause and effect must be considered when evaluating the 
utility of the diagnostic biomarkers and the role of BPH as a disease continuum-intermediate 
may be particularly important in this respect.
The majority of the included studies reported distinct clustering by metabolome profiles, 
with differentiation status playing an important role in the determination of the profiles (32). 
Where biomarkers were developed, high AUCs; that in many cases outperformed PSA, were 
reported. This is in line with the generally accepted consensus that the metabolome 
represents a rich source for biomarker identification. However replication, particularly 
between biological media, and independent validation was lacking, multiple testing was 
rarely accounted for and the extent to which the reported findings may represent false 
positives is difficult to assess.
This was true even of one of the most commonly cited ‘metabolomics successes’ sarcosine, 
and the importance of technical issues in metabolomics studies is perhaps best exemplified 
by the debate over the potential use of this biomarker. Nevertheless a number of metabolites 
and pathways were repeatedly implicated by the studies with amino acid and lipid 
metabolism appearing to play a predominant role in carcinogenesis, progression and 
recurrence. Caution must be taken to ensure such findings do not merely reflect the most 
abundant, easy to measure or stable metabolites, although encouragingly a number of the 
studies indicate that the ‘metabolome’ of prostate cancer is distinct from that of other 
malignancies.
These challenges inherent to metabolomics extend even beyond those facing researchers 
when they first tried to characterize the human genome, due to the additional temporal 
component as well as issues regarding the stability, variation and plasticity of the 
metabolites (107). Therefore collaboration between groups conducting metabolomics-based 
studies is vital, both in terms of standardizing the optimal methods and analytical strategies, 
to maximize reproducibility, reliability and sensitivity and also for replication or the accrual 
of sufficient sample sizes for these highly dimensional studies (108).
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Clinical translation remains the end goal, but a number of important factors remain to be 
considered before this is feasible for the current studies, including issues of bias, 
confounding, and generalizability. Beyond the efficacy of a biomarker the feasibility of 
clinical translocation must also be considered. More than two decades since PSA testing was 
introduced no such biomarkers have been clinically approved (109). In fact it may be that the 
utility of the metabolites and metabolite profiles identified here lies not in their clinical 
usage but in the insights they provide into the mechanisms of carcinogenesis. For example 
McDunn et al. (16) postulated that there may be a variety of pathways that lead to the 
development and progression of prostate cancer, and therefore multiple metabolite models 
that are able to predict the outcome of interest in a certain subpopulations. The differing 
results and lack of replication in the included studies may support this theory.
In conclusion, the study of the metabolome of prostate cancer remains in the early phases, 
but could yet represent an important tool both in the understanding of prostate cancer 
development and progression, and in the development of biomarkers to aid its management.
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et
ab
ol
ite
 
le
v
el
s r
em
ai
ne
d 
ab
no
rm
al
 in
 p
at
ie
nt
s w
ho
 d
ev
el
op
ed
 C
RP
C 
w
ith
in
 
1 
ye
ar
Va
lid
at
io
n 
cu
rre
nt
ly
 o
ng
oi
ng
D
CA
, G
CD
C,
 L
 -t
ry
pt
op
ha
n,
 D
PA
, 
ar
ac
hi
do
ni
c 
ac
id
, d
eo
xy
cy
tid
in
e 
tri
-
ph
os
ph
at
e,
 a
nd
 p
yr
id
in
ol
in
e 
re
pr
es
en
t 
po
te
nt
ia
l b
io
m
ar
ke
rs
 fo
r e
v
al
ua
tin
g 
pa
tie
nt
 re
sp
on
se
 to
 e
nd
oc
rin
e 
th
er
ap
y.
 
Th
es
e 
re
su
lts
 su
gg
es
t a
 ro
le
 fo
r 
ch
ol
es
te
ro
l i
n 
PC
A
 p
ro
gr
es
sio
n
M
on
du
l e
t a
l. 
(20
14
)
42
0 
m
et
ab
ol
ite
s
Ci
rc
ul
at
in
g 
1-
ste
ar
oy
lg
ly
ce
ro
l w
as
 in
v
er
se
ly
 a
ss
oc
ia
te
d 
w
ith
 th
e 
ris
k 
of
 d
ev
el
op
in
g 
pr
os
ta
te
 c
an
ce
r u
p 
to
 2
3 
ye
ar
s a
fte
r b
lo
od
 
co
lle
ct
io
n.
 T
he
 m
ag
ni
tu
de
 o
f t
hi
s a
ss
oc
ia
tio
n 
di
d 
no
t d
iff
er
 b
y 
di
se
as
e 
ag
gr
es
siv
en
es
s.
 T
he
re
 w
as
 a
lso
 su
gg
es
tiv
e 
in
v
er
se
 
as
so
ci
at
io
ns
 fo
r g
ly
ce
ro
l a
nd
 a
lp
ha
-k
et
og
lu
ta
ra
te
.
O
nl
y 
th
e 
as
so
ci
at
io
n 
be
tw
ee
n 
al
ph
a-
ke
to
gl
ut
ar
at
e 
an
d 
ag
gr
es
siv
e 
pr
os
ta
te
 c
an
ce
r w
as
 r
ep
lic
at
ed
 in
 a
 
su
bs
eq
ue
nt
 st
ud
y 
in
cl
ud
in
g 
di
ffe
re
nt
 p
ar
tic
ip
an
ts 
fro
m
 th
e 
sa
m
e 
po
pu
la
tio
n.
Th
e 
re
su
lts
 su
pp
or
t a
 ro
le
 fo
r 
dy
sr
eg
ul
at
io
n 
of
 li
pi
d 
m
et
ab
ol
ism
 in
 
th
e 
de
v
el
op
m
en
t o
f p
ro
sta
te
 c
an
ce
r
M
on
du
l e
t a
l. 
(20
15
)
62
6 
m
et
ab
ol
ite
s
St
ro
ng
 in
v
er
se
 a
ss
o
ci
at
io
ns
 b
et
w
ee
n 
en
er
gy
 a
nd
 li
pi
d 
m
et
ab
ol
ite
s 
pa
rti
cu
la
rly
 g
ly
ce
ro
ph
os
ph
ol
ip
id
s a
nd
 fa
tty
 a
ci
ds
 a
nd
 a
gg
re
ss
iv
e 
ca
n
ce
r 
w
er
e 
o
bs
er
ve
d 
w
ith
 a
gg
re
ss
iv
e 
di
se
as
e 
ris
k.
 T
hy
ro
xi
ne
 a
nd
 
tr
im
et
hy
la
m
in
e 
ox
id
e 
w
er
e 
as
so
ca
ite
d 
w
ith
 a
gg
re
ss
iv
e 
di
se
as
e 
ris
k 
w
hi
le
 A
lp
ha
-k
et
og
lu
ta
ra
te
 a
nd
 c
itr
at
e 
w
er
e 
in
v
er
se
ly
 a
ss
oc
ia
te
d.
 
M
et
ab
ol
ite
s a
ss
oc
ia
te
d 
w
ith
 n
on
ag
gr
es
siv
e 
ca
n
ce
rs
 in
cl
ud
ed
 2
′-
de
ox
yu
rid
in
e,
 a
de
no
sin
e 
50
 -m
on
op
ho
sp
ha
te
 (A
M
P)
, 1
1-
de
hy
dr
oc
or
tic
os
te
ro
ne
, 2
1-
hy
dr
ox
yp
re
gn
en
ol
on
e 
m
on
os
ul
fa
te
, 
co
tin
in
e 
an
d 
hy
dr
ox
yc
ot
in
in
e.
M
et
a-
an
al
ys
es
 w
ith
 th
e 
fin
di
ng
s o
f 
a 
pr
ev
io
us
 st
ud
y 
co
nf
irm
ed
 a
 ro
le
 
fo
r g
ly
ce
ro
ph
os
ph
ol
ip
id
s a
nd
 lo
ng
 
ch
ai
n 
fa
tty
 a
ci
ds
Pr
os
pe
ct
iv
e 
st
ud
y 
da
ta
 in
di
ca
te
 th
at
 
se
v
er
al
 c
irc
ul
at
in
g 
gl
yc
er
op
ho
sp
ho
lip
id
, f
at
ty
 a
ci
d,
 
en
er
gy
 a
nd
 re
la
te
d 
m
et
ab
ol
ite
s a
re
 
in
v
er
se
ly
 a
ss
oc
ia
te
d 
w
ith
 a
gg
re
ss
iv
e 
pr
os
ta
te
 c
an
ce
r u
p 
to
 2
0 
ye
ar
s p
rio
r t
o 
di
ag
no
sis
. M
et
ab
ol
ite
 a
ss
oc
ia
tio
ns
 
v
ar
y 
by
 c
an
ce
r a
gg
re
ss
iv
en
es
s.
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